M31.5
Giant cell arteritis with polymyalgia rheumatica
Clinical Classification Guidelines
Medical Intelligence & Overview
Giant Cell Arteritis (GCA), also known as temporal arteritis, is a condition characterized by inflammation of the large and medium-sized arteries, primarily affecting the head and neck. When GCA occurs along with polymyalgia rheumatica (PMR), a condition that causes muscle pain and stiffness, the combined diagnosis is referred to as 'Giant Cell Arteritis with Polymyalgia Rheumatica.' This condition typically affects adults over 50 and requires prompt medical attention to prevent serious complications, such as vision loss. Recognizing the symptoms and understanding the condition can help in timely management and treatment.
Causes & Symptoms
Clinical Causes: The exact cause of giant cell arteritis with polymyalgia rheumatica is unknown. It involves an abnormal immune response, leading to inflammation of blood vessels. Genetic factors may contribute, as it is more common in individuals with a family history of autoimmune disorders. Environmental triggers, such as infections, might also influence its development. Age-related changes in immune system functioning are considered a factor, as the condition primarily affects older adults.
Key Symptoms: Headaches, particularly over the temples Scalp tenderness and scalp sensitivity Jaw pain during chewing Vision problems, including blurred or double vision, or sudden loss of vision Muscle pain and stiffness, especially in the shoulders and hips (characteristic of polymyalgia rheumatica) Fatigue and general feeling of malaise Weight loss and fever in some cases
Diagnostic & Treatment
Diagnosis Path: Diagnosing giant cell arteritis with polymyalgia rheumatica involves a combination of clinical assessment, blood tests, and biopsies. Typical steps include: - A thorough medical history and physical examination focused on symptoms and artery tenderness - Blood tests such as ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), which are usually elevated - Temporal artery biopsy to examine the artery tissue for inflammation and giant cells - Imaging tests like ultrasound, MRI, or PET scans to visualize affected arteries Timely diagnosis is crucial to initiate treatment and prevent complications, particularly vision loss.
Treatment Protocols: Treatment aims to reduce inflammation and prevent complications, especially in the eyes. It generally involves: - High-dose corticosteroids, such as prednisone, prescribed promptly upon suspicion of the condition - Gradual tapering of steroid doses based on response and side effects - Monitoring for side effects of long-term steroid use - In some cases, additional medications like immunosuppressants may be considered - Regular follow-up appointments to assess for symptom resolution and detect potential relapses - Other supportive care to manage symptoms and side effects of medications Early and consistent treatment significantly reduces the risk of severe complications, including blindness.
Clinical Advice & FAQs
Billing Guidance
Is M31.5 a billable ICD-10 code?
Yes, M31.5 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M31.5?
Clinical documentation must specify the nature of Giant cell arteritis with polymyalgia rheumatica and any associated comorbidities for accurate reporting.
Cite this Clinical Reference